BLRX
BioLineRx Ltd.NASDAQHealthcare$2.21+1.81%ClosedMarket Cap: $9.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.59
P/S
9.10
EV/EBITDA
-5.37
DCF Value
$0.24
FCF Yield
-76.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.1%
Operating Margin
-874.7%
Net Margin
-101.7%
ROE
-6.1%
ROA
-2.9%
ROIC
-30.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $195.2K | 46.9% | $-3.4M | $-1.4M | $-0.32 | — |
| FY 2025 | $1.2M | 36.2% | $-10.4M | $-1.2M | $-0.29 | — |
| Q3 2025 | $427.0K | 80.3% | $-2.2M | $-977.0K | $-0.22 | — |
| Q2 2025 | $304.0K | 76.3% | $-2.3M | $-3.9M | $-1.00 | — |
| Q1 2025 | $255.0K | 86.7% | $-2.4M | $5.1M | $0.06 | — |
| Q4 2024 | $11.7M | 48.2% | $-4.4M | $-3.2M | $-0.04 | — |
| FY 2024 | $28.9M | 68.0% | $-20.4M | $-9.2M | $-0.12 | — |
| Q3 2024 | $4.9M | 83.4% | $-5.4M | $-5.8M | $-0.07 | — |
| Q2 2024 | $5.4M | 83.4% | $-5.8M | $484.0K | $0.01 | — |
| Q1 2024 | $6.9M | 78.8% | $-4.8M | $-696.0K | $-0.01 | — |
| Q4 2023 | $4.8M | 23.1% | $-18.6M | $-13.9M | $-0.19 | — |
| FY 2023 | $4.8M | 23.1% | $-49.7M | $-60.6M | $-0.94 | — |